TrialsgrambetaRCTs are beautiful

CAPSTONE-1

2018

Baloxavir in Uncomplicated Influenza

In 1,436 outpatients aged 12–64 with uncomplicated influenza, a single dose of baloxavir shortened time to symptom alleviation compared with placebo with much faster viral-load decline.

Result

Primary endpoint: Time to alleviation of symptoms

Median 53.7 h vs 80.2 h (p<0.001). Treatment-emergent PA-I38T/M/F polymerase substitutions in 9.7 % of baloxavir recipients.

Original publication
Subtopic
Influenza
Design
Double-blind RCT
Relevance
Supporting: context rather than must-know.
Source
Hayden FG, et al. N Engl J Med. 2018;379(10):913-923.doi 10.1056/NEJMoa1716197

Discussion & critique

First single-dose, novel-class anti-influenza, used in selected outpatients; resistance signal warrants monitoring.